References
- World Health Organization. WHO coronavirus (COVID-19 dashboard). 2023 Sep 26 [cited 2023 Sep 26]. Available from: https://covid19.who.int/?adgroupsurvey=%7Badgroupsurvey%7D&gclid=Cj0KCQiAw8OeBhCeARIsAGxWtUxR9wuVfKmK8awaDLSRrSm65bKiEJOcvWX34XpP2LX4eD_sR9ZfUqAaArNPEALw_wcB
- Altmann DM, Boyton RJ. COVID-19 vaccination: the road ahead. Science. 2022 Mar 11;375(6585):1127–1132. doi: 10.1126/science.abn1755
- Kelly SL, Le Rutte EA, Richter M, et al. COVID-19 vaccine booster strategies in light of emerging viral variants: frequency, timing, and target groups. Infect Dis Ther. 2022 Oct;11(5):2045–2061.
- Zarebska-Michaluk D, Hu C, Brzdek M, et al. COVID-19 vaccine booster strategies for omicron SARS-CoV-2 variant: Effectiveness and future prospects. Vaccines (Basel). 2022, Jul 30;10(8):1223. doi: 10.3390/vaccines10081223
- Zhu Y, Liu S, Zhang D. Effectiveness of COVID-19 vaccine booster shot compared with non-booster: a meta-analysis. Vaccines (Basel). 2022 Aug 25;10(9):1396.
- Arbel R, Peretz A, Sergienko R, et al. Effectiveness of a bivalent mRNA vaccine booster dose to prevent severe COVID-19 outcomes: a retrospective cohort study. Lancet Infect Dis. 2023, Apr 13;23(8):914–921. doi: 10.1016/S1473-3099(23)00122-6
- Kinugasa Y, Llamas-Covarrubias MA, Ozaki K, et al. Post-coronavirus disease 2019 syndrome in Japan: an observational study using a medical database. Japan Med Assoc J. 2023;6(4):416–425. doi: 10.31662/jmaj.2023-0048
- Tomioka K, Uno K, Yamada M. Association between vaccination status and severe health consequences among community-dwelling COVID-19 patients during omicron BA.1/BA.2 and BA.5-predominant periods in Japan. Environ Health Prev Med. 2023;28:35. doi: 10.1265/ehpm.23-00061
- Karako K, Song P, Chen Y, et al. An average of nearly 200,000 new infections per day over a six-week period: what is the impact of such a severe COVID-19 pandemic on the healthcare system in Japan? Biosci Trends. 2022, Nov 20;16(5):371–373. doi: 10.5582/bst.2022.01390
- Yamaguchi S, Okada A, Sunaga S, et al. Impact of COVID-19 pandemic on healthcare service use for non-COVID-19 patients in Japan: retrospective cohort study. BMJ Open. 2022, Apr 24;12(4):e060390. doi: 10.1136/bmjopen-2021-060390
- Ministry of Health., Labour and welfare. Temporary vaccination implementation guidelines related to COVID-19 2023. 2023 Dec 4 [cited 2024 Feb 8]. Available from: https://www.mhlw.go.jp/content/001174286.pdf
- Ministry of Health., Labour and welfare. COVID-19 vaccination Q&A 2023. 2023 Dec 25 [cited 2024 Feb 8]. Available from: https://www.cov19-vaccine.mhlw.go.jp/qa/0180.html
- Ministry of Health., Labour and welfare. Measures to be taken after the transition of the COVID-19 to class 5 infectious diseases. 2023 Sep 15 [cited 2023 Sep 26]. Available from: https://www.mhlw.go.jp/stf/corona5rui.html
- Di Fusco M, Marczell K, Thoburn E, et al. Public health impact and economic value of booster vaccination with pfizer-BioNTech COVID-19 vaccine, bivalent (original and omicron BA.4/BA.5) in the United States. J Med Econ. 2023 Jan;26(1):509–524.
- Di Fusco M, Marczell K, Deger KA, et al. Public health impact of the pfizer-BioNTech COVID-19 vaccine (BNT162b2) in the first year of rollout in the United States. J Med Econ. 2022 Jan;25(1):605–617.
- Link-Gelles R, Weber ZA, Reese SE, et al. Estimates of bivalent mRNA vaccine durability in preventing COVID-19-associated hospitalization and critical illness among adults with and without immunocompromising conditions - VISION network, September 2022–April 2023. MMWR Morb Mortal Wkly Rep. 2023 May 26;72(21):579–588. doi: 10.15585/mmwr.mm7221a3
- Core 2 Health. Guideline for preparing cost-effectiveness evaluation to the central social insurance medical council. 2023 Jan 19 [cited 2023 Sep 26]. Available from: https://c2h.niph.go.jp/tools/guideline/guideline_en.pdf
- Ministry of Health, Labour and Welfare of Japan, Social welfare and War victims’ Relief Bureau, Department of Health and Welfare for Persons with Disabilities. 2016 survey results on difficulties on living-national survey of people living with disability at home. Tokyo, Japan: Ministry of Health, Labour and Welfare of Japan. 2016 [cited 2023 Jun 18]. Available from: https://www.mhlw.go.jp/toukei/list/dl/seikatsu_chousa_c_h28.pdf
- e-Stat (Portal Site of Official Statistics of Japan). Population estimates. 2020 [cited 2023 Sep 26]. Available from: https://www.e-stat.go.jp/stat-search/files?page=1&layout=datalist&toukei=00200524&tstat=000000090001&cycle=7&year=20200&month=0&tclass1=000001011679&result_back=1&tclass2val=0
- Ministry of Health, Labour and welfare. Announcement on the COVID-19 vaccination program in Spring 2023. 2023 Apr 26 [cited 2023 Sep 26]. Available from: https://www.mhlw.go.jp/content/001068244.pdf
- Ministry of Health, Labour and Welfare. 2020 patient survey (confirmed numbers). 2022 Jun 30 [cited 2023 Sep 26]. Available from: https://www.mhlw.go.jp/toukei/saikin/hw/kanja/20/index.html
- Statistics Bureau of Japan. 2020 population census. 2021 Nov 30 [cited 2023 Sep 26]. Available from: https://www.stat.go.jp/english/data/kokusei/2020/summary.html
- Prime Minister’s Office of Japan. Ongoing topics on COVID-19 vaccines. [cited 2023 Jun 17]. Available from: https://www.kantei.go.jp/jp/headline/kansensho/vaccine.html
- National Institute of Infectious Diseases. Fifth preliminary report of a case-control study examining the efficacy of COVID-19 vaccines: the efficacy of a bivalent vaccine against omicron 2022. 2022 Dec 13 [cited 2022 Sep 26]. Available from: https://www.niid.go.jp/niid/ja/2019-ncov/2484-idsc/11688-covid19-9999.html
- Maeda H, Saito N, Igarashi A, et al. Effectiveness of mRNA COVID-19 vaccines against symptomatic SARS-CoV-2 infections during the SARS-CoV-2 omicron BA.1 and BA.2 epidemic in Japan: vaccine effectiveness real-time surveillance for SARS-CoV-2 (VERSUS). Expert Rev Vaccines. 2023 Jan;22(1):288–298.
- Solante R, Alvarez-Moreno C, Burhan E, et al. Expert review of global real-world data on COVID-19 vaccine booster effectiveness and safety during the omicron-dominant phase of the pandemic. Expert Rev Vaccines. 2023 Jan;22(1):1–16.
- National Institute of Infectious Diseases. Current situation of infection. 2023 Jun 16 [cited 2023 Jun 17]. Available from: https://www.niid.go.jp/niid/en/2019-ncov-e.html
- Cabinet Secretariat, Japan. COVID-19 information and resources 2023 [cited 2023 Jun 17]. Available from: https://corona.go.jp/dashboard/
- COVID-19 Infectious Disease Advisory Board Secretariat. The third survey of antibody prevalence rate of COVID-19 using residual blood from test specimens at the time of blood donation (preliminary report, summary) 2023. 2023 Jun 16 [cited 2023 Sep 26]. Available from: https://www.mhlw.go.jp/content/001109157.pdf
- Ministry of Health, Labour and Welfare. Visualizing the data: information on COVID-19 infections. 2023 [cited 2023 Sep 26]. Available from: https://covid19.mhlw.go.jp/en/
- Hiroshima Prefecture Health and Welfare Bureau. Hiroshima prefecture COVID-19 J-SPEED (J-SPEED: surveillance in post extreme emergencies and disasters, Japan version) data analysis from the 7th wave. 2022 [cited 2023 Sep 26]. Available from: https://www.mhlw.go.jp/content/10900000/000975398.pdf
- Ishikawa Infectious Disease Information Center. The status of SARS-CoV-2 infection in Ishikawa Prefecture. 2022 [cited 2023 Sep 26]. Available from: https://www.pref.ishikawa.lg.jp/kansen/documents/202207kansenzyokyo.pdf
- Osaka Prefectural Department of Health and Medical Care. The current situation of infection and medical treatment(COVID-19). 2023 [cited 2023 Sep 26]. Available from: https://www.mhlw.go.jp/content/10900000/001039367.pdf
- Matsunaga N, Hayakawa K, Asai Y, et al. Clinical characteristics of the first three waves of hospitalised patients with COVID-19 in Japan prior to the widespread use of vaccination: a nationwide observational study. Lancet Reg Health West Pac. 2022 May 01;22:100421.
- Tesoriero JM, Swain C-A, Pierce JL, et al. COVID-19 outcomes among persons living with or without diagnosed HIV infection in New York State. JAMA Netw Open. 2021;4(2):e2037069–e2037069. doi: 10.1001/jamanetworkopen.2020.37069
- Ssentongo P, Heilbrunn ES, Ssentongo AE, et al. Epidemiology and outcomes of COVID-19 in HIV-infected individuals: a systematic review and meta-analysis. Sci Rep. 2021 Mar 18;11(1):6283. doi: 10.1038/s41598-021-85359-3
- The 49th new coronavirus infectious disease control advisory board. Ministry of Health, Labour and Welfare. Responses to risk factors for exacerbation of COVID-19-positive patients 2021 [cited 2023 Sep 26]. Available from: https://www.mhlw.go.jp/content/10900000/000823697.pdf
- Yamanashi Prefecture Infectious Disease Control Center, Welfare and Health Department. Results of the COVID-19 sequelae (summary) 2022 [cited 2023 Sep 26]. Available from: https://www.pref.yamanashi.jp/kansensho/documents/coronavirus_kouisho2.pdf
- Sugiyama A, Miwata K, Kitahara Y, et al. Long COVID occurrence in COVID-19 survivors. Sci Rep. 2022 Apr 11;12(1):6039. doi: 10.1038/s41598-022-10051-z
- Organisation for Economic Co-operation and Development. Exchange rates. [cited 2023 Sep 26]. Available from: https://data.oecd.org/conversion/exchange-rates.htm
- Ministry of Health, Labour and welfare. Cost-effectiveness estimation method for vaccination. [cited 2023 Sep 26]. Available from: https://www.mhlw.go.jp/stf/shingi/2r98520000014ryv-att/2r98520000014sdi.pdf
- Ministry of Health, Labour and Welfare. Various information of medical fee. 2023 [cited 2023 Jul 27]. Available from: https://shinryohoshu.mhlw.go.jp/shinryohoshu/
- Medical Data Vision. MDV database. [cited 2023 Sep 26]. Available from: https://en.mdv.co.jp/
- Ministry of Health, Labour and Welfare. Reports of suspected side effects of the COVID-19 vaccine. [cited 2023 Jul 9]. Available from: https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/vaccine_hukuhannou-utagai-houkoku.html
- Tsutsui H, Sakamaki H, Momomura S, et al. Cost-effectiveness analysis of empagliflozin in patients with heart failure with reduced ejection fraction in Japan based on the EMPEROR-Reduced trial. Journal of Cardiology. 2023, ;81(6):522–530 . doi: 10.1016/j.jjcc.2023.02.007 26 Sep 2023 https://doi.org/10.1016/j.jjcc.2023.02.007
- e-Stat (Portal Site of Official Statistics of Japan). Basic statistical survey of wage structure. 2021 [cited 2023 Sep 26]. Available from: https://www.e-stat.go.jp/stat-search/files?page=1&layout=datalist&toukei=00450091&tstat=000001011429&cycle=0&tclass1=000001164106&tclass2=000001164107&tclass3=000001164108&tclass4val=0%E8%A1%A81%2C%20%E7%94%B7%E5%A5%B3%E8%A8%88
- World Health Organization. A clinical case definition of post COVID-19 condition by a Delphi consensus, 6 October 2021. Geneve, Switzerland: World Health Organization; 2021 [cited26 Sep 2023]. Availabe from: https://www.who.int/publications/i/item/WHO-2019-nCoV-Post_COVID-19_condition-Clinical_case_definition-2021.1
- Aoki T, Sugiyama Y, Mutai R, et al. Impact of primary care attributes on hospitalization during the COVID-19 pandemic: a nationwide prospective cohort study in Japan. Ann Fam Med. 2023 Jan;21(1):27–32.
- Shiroiwa T, Noto S, Fukuda T. Japanese population norms of EQ-5D-5L and health utilities index mark 3: disutility catalog by disease and symptom in community settings. Value Health. 2021 Aug;24(8):1193–1202. doi: 10.1016/j.jval.2021.03.010
- Yamamoto H, Tanaka S, Kasugai D, et al. Physical function and mental health trajectories in COVID-19 patients following invasive mechanical ventilation: a prospective observational study. Scientific reports. 2022 [cited2023 Sep];13(1):14529. doi: 10.1038/s41598-023-41684-3
- National Institute of Infectious Diseases. Active epidemiological investigation of COVID-19 caused by SARS-CoV-2 omicron variant (6th report): virological and serological characteristics. 2022 [cited 2024 Feb 9]. Available from: https://www.niid.go.jp/niid/images/epi/corona/76/covid19-76.pdf
- Shiroiwa T, Sung YK, Fukuda T, et al. International survey on willingness-to-pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness? Health Econ. 2010 Apr;19(4):422–437.
- Ministry of Health, Labour and Welfare. Target population of COVID-19 vaccination. 2023 [cited 2024 Jan 31]. Available from: https://www.cov19-vaccine.mhlw.go.jp/qa/uploads/0148_231130.pdf
- Wallace M. COVID-19 vaccine policy and next steps: centers for disease control and prevention. 2023 [cited 2024 Jan 31]. Available from: https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2023-10-25-26/03-COVID-Wallace-508.pdf
- World Health Organization. WHO roadmap on uses of COVID-19 vaccines in the context of omicron and high population immunity 2023. 6th ed. 2023 Nov 10 [cited 2024 Jan 31]. Available from: https://iris.who.int/bitstream/handle/10665/373987/WHO-2019-nCoV-Vaccines-SAGE-Prioritization-2023.2-eng.pdf?sequence=1
- Marra AR, Kobayashi T, Callado GY, et al. The effectiveness of COVID-19 vaccine in the prevention of post-COVID conditions: a systematic literature review and meta-analysis of the latest research. Antimicrob Steward Healthc Epidemiol. 2023;3(1):e168. doi: 10.1017/ash.2023.447
- Li R, Liu H, Fairley CK, et al. mRNA-based COVID-19 booster vaccination is highly effective and cost-effective in Australia. Vaccine. 2023, Apr 6;41(15):2439–2446. doi: 10.1016/j.vaccine.2023.01.075
- Li R, Liu H, Fairley CK, et al. Cost-effectiveness analysis of BNT162b2 COVID-19 booster vaccination in the United States. Int J Infect Dis. 2022 Jun;119:87–94.
- Mendes D, Chapman R, Aruffo E, et al. Public health impact of UK COVID-19 booster vaccination programs during omicron predominance. Expert Rev Vaccines. 2023 Jan;22(1):90–103.